Min Ho Lee1, Sang Duk Hong2, Kyung In Woo3, Yoon-Duck Kim3, Jung Won Choi1, Ho Jun Seol1, Jung-Il Lee1, Hyung Jin Shin1, Do-Hyun Nam1, Doo-Sik Kong4. 1. Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. 2. Department of Otorhinolaryngology-Head and Neck Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. 3. Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. 4. Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Electronic address: neurokong@gmail.com.
Abstract
BACKGROUND: Based on our experience with the endoscopic endonasal approach (EEA) and transorbital approach (TOA) for middle cranial fossa tumors, we evaluated the efficacy and limitations of visualization and the clinical outcomes associated with the approaches depending on the surgical corridors. In addition, we determined the optimal strategy for each approach. METHODS: Between September 2015 and May 2018, we retrospectively reviewed clinical outcomes in 21 patients who underwent minimally invasive endoscopic surgery for middle cranial fossa tumors involving the cavernous sinus. We classified the endoscopic approaches into 4 groups: endonasal quadrangular transcavernous (type I), endonasal infratemporal (type II), transclival medial-to-lateral (type III), and transorbital (type IV) routes. Displacement of the internal carotid artery, extent of tumor involvement, and the surgical corridor to the tumor direction were the primary determinants of the approach. RESULTS: The study enrolled 21 patients. Based on the classification of approaches, 6 patients underwent surgery via type I, 5 via type II, 1 via type III, 7 via type IV, and 2 via a combined approach. Among the 21 patients, gross total resection was performed in 12 (57.1%), subtotal resection in 6, and partial resection in 3. Comparison of the type I (EEA) with the type 4 (TOA) route showed that the gross total resection rate with the EEA was 33.3% compared with 71.4% with the TOA (P = 0.286). CONCLUSIONS: Endoscopic surgery can be considered an alternative with acceptable sequelae and reduced morbidity for the management of middle cranial fossa tumors. Surgeons should be aware of the strengths and weaknesses of each surgical corridor and select the optimal approach for each patient based on the tumor.
BACKGROUND: Based on our experience with the endoscopic endonasal approach (EEA) and transorbital approach (TOA) for middle cranial fossa tumors, we evaluated the efficacy and limitations of visualization and the clinical outcomes associated with the approaches depending on the surgical corridors. In addition, we determined the optimal strategy for each approach. METHODS: Between September 2015 and May 2018, we retrospectively reviewed clinical outcomes in 21 patients who underwent minimally invasive endoscopic surgery for middle cranial fossa tumors involving the cavernous sinus. We classified the endoscopic approaches into 4 groups: endonasal quadrangular transcavernous (type I), endonasal infratemporal (type II), transclival medial-to-lateral (type III), and transorbital (type IV) routes. Displacement of the internal carotid artery, extent of tumor involvement, and the surgical corridor to the tumor direction were the primary determinants of the approach. RESULTS: The study enrolled 21 patients. Based on the classification of approaches, 6 patients underwent surgery via type I, 5 via type II, 1 via type III, 7 via type IV, and 2 via a combined approach. Among the 21 patients, gross total resection was performed in 12 (57.1%), subtotal resection in 6, and partial resection in 3. Comparison of the type I (EEA) with the type 4 (TOA) route showed that the gross total resection rate with the EEA was 33.3% compared with 71.4% with the TOA (P = 0.286). CONCLUSIONS: Endoscopic surgery can be considered an alternative with acceptable sequelae and reduced morbidity for the management of middle cranial fossa tumors. Surgeons should be aware of the strengths and weaknesses of each surgical corridor and select the optimal approach for each patient based on the tumor.
Authors: Thomaz E Topczewski; Alberto Di Somma; Jose Pineda; Abel Ferres; Jorge Torales; Luis Reyes; Ruben Morillas; Domenico Solari; Luigi Maria Cavallo; Paolo Cappabianca; Joaquim Enseñat; Alberto Prats-Galino Journal: Acta Neurochir (Wien) Date: 2020-06-15 Impact factor: 2.216
Authors: Won-Jae Lee; Sang Duk Hong; Kyung In Woo; Ho Jun Seol; Jung Won Choi; Jung-Il Lee; Do-Hyun Nam; Doo-Sik Kong Journal: Acta Neurochir (Wien) Date: 2022-04-29 Impact factor: 2.816
Authors: Gianluca Lorenzo Fabozzi; Elena d'Avella; Matias Burroni; Antonio Romano; Luigi Maria Cavallo; Domenico Solari Journal: Front Surg Date: 2022-07-21
Authors: Giulia Guizzardi; Alberto Di Somma; Matteo de Notaris; Francesco Corrivetti; Juan Carlos Sánchez; Isam Alobid; Abel Ferres; Pedro Roldan; Luis Reyes; Joaquim Enseñat; Alberto Prats-Galino Journal: Front Oncol Date: 2022-09-02 Impact factor: 5.738
Authors: Alperen Vural; Andrea Luigi Camillo Carobbio; Marco Ferrari; Vittorio Rampinelli; Alberto Schreiber; Davide Mattavelli; Francesco Doglietto; Barbara Buffoli; Luigi Fabrizio Rodella; Stefano Taboni; Michele Tomasoni; Tommaso Gualtieri; Alberto Deganello; Lena Hirtler; Piero Nicolai Journal: Neurosurg Rev Date: 2021-01-22 Impact factor: 3.042